Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-09-20

Clinical Trial Update: Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis [Phase 3]

View source ↗

Summary

Phase 3 trial of sorafenib tosylate in desmoid fibromatosis (desmoid tumors) completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sorafenib tosylate (sorafenib tosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Desmoid Fibromatosis | Phase 3 | Status: COMPLETED | Results posted: 2019-09-20